Add this topic to your myFT Digest for news straight to your inbox
Leadership change follows series of snags
Jordanian drugmaker undeterred despite pressure from Roxane purchase
UK-listed pharma group renegotiates price for US generics arm of Boehringer Ingelheim
Revenue growth from gout treatment colchicine ‘more gradual’ than expected
Jordanian group to pay a mixture of cash and shares to Boehringer
Jordanian drugmaker outgrows Mideast roots as it proves it can compete in Europe and US as well
Chief executive says money is available as pharma M&A spree may continue in 2015
International Edition